www.hivandhepatitis.com

IAS 2017: Demonstration Projects Explore Feasibility of PrEP for Adolescents in South Africa

One of the first studies to explore the acceptability, safety, and use of pre-exposure prophylaxis (PrEP) in adolescents in an African context has found that PrEP was safe and tolerable, although PrEP usage and adherence did tail off during the 12 months of the program.

Read more:

IAS 2017: World On Track To Reach 90-90-90 Targets for HIV Treatment by 2020

The world is on track to reach global targets for reducing AIDS deaths and expanding HIV treatment access by 2020, but some regions of the world risk falling further behind due to lack of political commitment, UNAIDS announced in the run-up tothe 9th International AIDS Society Conference on HIV Science (IAS 2017) in Paris.

Read more:

IAS 2017: First Protease Inhibitor Combo Pill Maintains Viral Suppression

The first once-daily single-tablet regimen containing a protease inhibitor maintained viral suppression in almost everyone who switched after achieving undetectable HIV RNA on a multi-pill regimen, according to a report at the 9th International AIDS Society Conference on HIV Science (IAS 2017) last month in Paris.

Read more:

IAS 2017: Long-Acting Cabotegravir Shows Promise For HIV Prevention

A long-acting injectable formulation of cabotegravir given every 8 weeks produces high enough drugs levels in both men and women to offer protection against HIV, according to results from the HPTN 077 study presented this week at the 9th International AIDS Society Conference on HIV Science (IAS 2017) in Paris. But another injectable prevention candidate, long-acting rilpivirine, has been abandoned.

Read more:

IAS 2017: Another HIV Vaccine Efficacy Trial Will Start This Year

A year ago, one of the biggest pieces of prevention news at the Durban International AIDS Conference was the announcement that a large HIV vaccine efficacy study would start in South Africa. HVTN 702, now running, is only the eighth human vaccine efficacy trial ever run in the history of the HIV epidemic, and the first since 2009.

Read more:

IAS 2017: New HIV Infections Halved as Treatment Scales Up in Swaziland

New HIV infections have been cut in half in Swaziland since 2011, at the same time as the proportion of people on antiretroviral treatment with fully suppressed viral load has doubled, according to a report at the 9th International AIDS Society Conference on HIV Science (IAS 2017) this week in Paris. It is the first direct evidence that expanding HIV treatment results in fewer HIV infections in a country with a major epidemic, researchers said.

Read more:

IAS 2017: WHO Recommends Urgent Care Package for People with Advanced HIV Disease

A new package of measures to ensure rapid initiation of antiretroviral treatment and diagnosis of opportunistic infections has been recommended by the World Health Organization (WHO) to reduce the still high rates of death among people diagnosed with HIV at a very advanced stage of disease.

Read more:

IAS 2017: PrEP Still Protected People Who Had Less Sex in Ipergay Study

A sub-study of the French Ipergay trial of "on-demand" pre-exposure prophylaxis (PrEP) has found that PrEP was just as effective for participants who had sex less often than average, and so took PrEP less often, as long as they did take it when it was needed. The analysis was presented by trial statistician Guillemette Antoni at the 9th International AIDS Society Conference (IAS 2017) conference this week in Paris.

Read more:

IAS 2017: Improved Cryptococcal Meningitis Treatment Could Save Thousands of Lives

Urgent action is needed to improve access to the antifungal drug flucytosine, say investigators, following the presentation of the results of a trial showing that treatment containing flucytosine is superior to any other form of therapy in reducing the risk of death from cryptococcal meningitis in people with very advanced HIV disease.

Read more:

IAS 2017: South African Child Has Controlled HIV Off Treatment for 8.5 Years

A 9-year-old South African child who was diagnosed with HIV infection at 1 month of age and received HIV treatment for 40 weeks during infancy has suppressed the virus without anti-HIV drugs for 8 and a half years, scientists reported this week at the 9th IAS Conference on HIV Science (IAS 2017) in Paris.

Read more:

Coverage of the 2017 IAS Conference on HIV Science

HIVandHepatitis.com coverage of the 9th International AIDS Society Conference on HIV Science, July 23-26, 2017, in Paris.

Full coverage listing by topic

IAS 2017 website

7/31/17

IAS 2017: TAG Releases Annual HIV, Hepatitis C, and TB Pipeline Report

On July 18 the Treatment Action Group (TAG) announced the launch of its latest overview of investigational therapies for HIV, hepatitis C virus (HCV), and tuberculosis (TB).

Read more:

Coverage of the 2017 IAS Conference on HIV Science

HIVandHepatitis.com coverage of the 9th International AIDS Society Conference on HIV Science, July 23-26, 2017, in Paris.

Antiretroviral Therapy

• Doravirine Combo Pill Looks Good for Initial HIV Treatment
• Boosted Darunavir Plus Lamivudine Matches 3-Drug Regimen
• Trans Women Wary of Antiretroviral Drug and Hormone Interactions
• Novel Long-Acting Drug Shows Promise for HIV Treatment and PrEP
• First Protease Inhibitor Combo Pill Maintains Viral Suppression
• Long-Acting Cabotegravir + Rilpivirine Looks Good for HIV ART
• New HIV Integrase Inhibitor Bictegravir Works Well for First-Line Treatment IAS

HIV Cure Research

• Cancer Research May Offer Clues for HIV Cure Research -- and Vice Versa
• Why Curing Cancer May Be Like Curing HIV -- and May Be As Difficult
• VRC01 Antibody Can Delay But Not Prevent HIV Rebound
• South African Child Has Controlled HIV Off Treatment for 8.5 Years

HIV Prevention

• Experts Agree that Intermittent Oral PrEP Probably Won't Work for Women
• Who Are Trans Women Acquiring HIV From?
• PrEP Use in U.S. Exceeds 100,000 in Gilead Pharmacy Survey
• Medical Male Circumcision for HIV Prevention Has Benefits for Women Too
• Another HIV Vaccine Efficacy Trial Will Start This Year
• Demonstration Projects Explore Feasibility of PrEP for Adolescents in South Africa
• Study of Gay Couples Shows No Transmissions from Undetectable HIV+ Partners
• Long-Acting Cabotegravir Shows Promise For HIV Prevention
• PrEP Still Protected People Who Had Less Sex in Ipergay Study

HIV-Related Conditions and Comorbidities

• Switch from Boosted Protease Inhibitor to Dolutegravir Reduces Lipids in People with HIV
• Acute Kidney Injury Uncommon on Tenofovir, No Link Seen to Bone Breaks
• People with HIV Are at Risk for Liver Fibrosis and Steatosis

HIV Epidemiology and Access to Care

• Aim for $90-$90-$90 Target on HIV, Hepatitis, and TB Drug Prices, Study Says
• Improved Cryptococcal Meningitis Treatment Could Save Thousands of Lives
• WHO Recommends Urgent Care Package for People with Advanced HIV Disease
• World On Track To Reach 90-90-90 Targets for HIV Treatment by 2020
• New HIV Infections Halved as Treatment Scales Up in Swaziland

Hepatitis C and HIV/HCV Coinfection

• Glecaprevir/Pibrentasvir Effective for People with HIV/HCV Coinfection
• Hepatitis C Treatment is Effective and Feasible in Africa

IAS 2017: IAS Conference on HIV Science Starts Sunday in Paris

The 9th International AIDS Society (IAS) Conference on HIV Science will take place July 23-26 at the Palais des Congrèsin Paris. HIVandHepatitis.com and aidsmap will be providing joint on-site coverage next week. Follow breaking news via @HIVandHeptitis on Twitter. IAS will be webcasting plenary sessions and daily press conferences.

Read more:

IAS 2017: Study of Gay Men Shows No Transmissions from Undetectable HIV+ Partners

A study of 343 gay couples, where one partner had HIV and the other did not, has not found a single case of HIV transmission in 16,889 acts of condomless anal sex, according to a presentation at the 9th International AIDS Society Conference on HIV Science (IAS 2017) this week in Paris.

Read more:

HR17: Combining Drug Addiction Treatment and Perinatal HIV Prevention Leads to Good Outcomes

An integrated program offering medication-assisted drug addiction treatment and services aimed at preventing mother-to-child HIV transmission led to improved outcomes for opioid-dependent HIV-positive mothers and their babies, according to a presentation at the 25th Harm Reduction International Conference this month in Montreal.

Read more:

IAS 2017: Long-Acting Cabotegravir + Rilpivirine Looks Good for HIV ART

Two long-acting injectable antiretrovirals, cabotegravir and rilpivirine, administered once every 4 or 8 weeks maintained viral suppression in about 90% of people who started therapy with an undetectable viral load, according to the latest results from the LATTE-2 trial, presented at the 9th International AIDS Society Conference on HIV Science this week in Paris and published simultaneously in The Lancet.

Read more:

Coverage of the 2017 Pediatric Academic Societies Meeting

HIVandHepatitis.com coverage of the 2017 Pediatric Academic Societies Meeting, May 6-9, 2017, in San Francisco.

• Many Doctors Wary of Providing PrEP for Young Patients
• Sofosbuvir Plus Ribavirin Cures Teens with Genotype 2 or 3 Hepatitis C
• Children on Immunosuppressive Therapy May Lose Hepatitis B Vaccine Protection 
• Vaccine Reduces Human Papillomavirus Prevalence Among Young Women
• New Approaches Help Babies with Opioid Withdrawal Syndrome

IAS 2017: New HIV Integrase Inhibitor Bictegravir Works Well for First-Line Treatment

A single-tablet regimen containing the experimental integrase inhibitor bictegravir was as effective as 2 widely used approved regimens for first-time therapy in a pair of Phase 3 clinical trials, according to presentations at the 9th International AIDS Society Conference on HIV Science (IAS 2017) this week in Paris.

Read more:

Coverage of the 2017 Harm Reduction International Conference

HIVand Hepatitis.com coverage of the 2017 Harm Reduction International Conference, May 14-17, 2017, in Montreal.

Full coverage listing

HR17 website

5/31/17